Cargando…
Mebendazole Impedes the Proliferation and Migration of Pancreatic Cancer Cells through SK1 Inhibition Dependent Pathway
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates and requires the development of highly efficacious medications that can improve the efficiency of existing treatment methods. In particular, in PDAC, resistance to conventional chemotherapy reduces the effectiveness of an...
Autores principales: | Limbu, Khem Raj, Chhetri, Rashmi Bhandari, Oh, Yoon Sin, Baek, Dong Jae, Park, Eun-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739667/ https://www.ncbi.nlm.nih.gov/pubmed/36500220 http://dx.doi.org/10.3390/molecules27238127 |
Ejemplares similares
-
Novel Dimer Derivatives of PF-543 as Potential Antitumor Agents for the Treatment of Non-Small Cell Lung Cancer
por: Kim, Su Bin, et al.
Publicado: (2022) -
Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer
por: Williamson, Tara, et al.
Publicado: (2021) -
Treatment of echinococcosis: albendazole and mebendazole – what else?
por: Hemphill, Andrew, et al.
Publicado: (2014) -
Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole
por: Speich, Benjamin, et al.
Publicado: (2016) -
Mebendazole Reduces Vascular Smooth Muscle Cell Proliferation and Neointimal Formation Following Vascular Injury in Mice
por: Wang, Jintao, et al.
Publicado: (2014)